# Cleveland Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cleveland-diagnostics

- Industry: Biotechnology
- Headquarters: Cleveland, US
- Website: www.clevelanddx.com
- Total disclosed funding: $17M
- Latest round: Series D (Feb 9, 2021)
- Investors on record: 2

## About

Founded in 2013 and based in Ohio, US, Cleveland Diagnostics, Inc. offers testing solutions for early detection of cancer and other high-grade disease. As of 2024, the company is headed by its CEO Arnon Chait. In January 2024, the firm raised USD 56.5 million in growth capital funding led by investor Novo Holdings, with participation from another investor Symbiotic Capital. Other investors also participated in the round. 

The product of Cleveland Diagnostics is the IsoPSA® test. This test is designed to offer a precise assessment of prostate cancer risk compared to traditional PSA tests. The test provides insights into the presence of aggressive cancer, thereby improving patient management and treatment decisions.

The company plans to use the January 2024 funding to accelerate its commercial and corporate development programs, including its early-detection oncology testing platform.

## Funding rounds

- Series D, Feb 9, 2021, $17M — LYFE Capital, Cleveland Clinic Ventures

## Investors

- LYFE Capital — Series D
- Cleveland Clinic Ventures (https://capitalatlas.ai/funds/cleveland-clinic-ventures) — Series D